Statin Decisions by ASCVD Risk: Who Gets a Statin, Which Intensity and How to Monitor

A statin decision comes down to which risk group the patient sits in, and the risk group sets the intensity. Patients with clinical ASCVD and those with LDL-C of 190 mg/dL or higher get a high-intensity statin without any risk calculation. Adults 40 to 75 with diabetes get at least a moderate-intensity statin. Everyone else in primary prevention is sorted by calculated 10-year risk, discussed with the patient, and refined with risk enhancers or a coronary artery calcium score when the decision is close.

The calculator and cut-offs changed in March 2026, when the ACC/AHA dyslipidemia guideline (Blumenthal et al.) replaced the 2018 cholesterol guideline. Exam items written before the change use the 2018 Pooled Cohort Equations; newer items use PREVENT. A candidate needs both.

What changed between 2018 and 2026

The PREVENT tiers sit lower because PREVENT estimates are lower than Pooled Cohort estimates for the same patient, not because the treatment threshold became more aggressive in absolute terms.

Assessment

Order a lipid panel (fasting or nonfasting is acceptable), then establish the risk group:

• Clinical ASCVD: acute coronary syndrome, prior myocardial infarction, stable or unstable angina, coronary or other revascularization, stroke or TIA, or symptomatic peripheral artery disease.
• Severe hypercholesterolemia: LDL-C of 190 mg/dL or higher. Think familial hypercholesterolemia and screen first-degree relatives.
• Diabetes: age 40 to 75. The 2026 guideline also recommends LDL-lowering therapy at 40 to 75 for CKD stage 3 to 4 and for HIV regardless of LDL-C.
• Everyone else: calculate 10-year risk.

Risk enhancers

Risk enhancers tip a borderline or intermediate decision toward treatment. The 2018 list includes family history of premature ASCVD (male relative before 55, female before 65), persistent LDL-C of 160 to 189 mg/dL, metabolic syndrome, CKD, history of preeclampsia or menopause before 40, chronic inflammatory disease (rheumatoid arthritis, psoriasis, HIV), South Asian ancestry, persistent triglycerides of 175 mg/dL or more, hs-CRP of 2.0 mg/L or more, lipoprotein(a) of 50 mg/dL or 125 nmol/L or more, apoB of 130 mg/dL or more, and an ankle-brachial index under 0.9. The 2026 guideline treats lipoprotein(a) of 125 nmol/L or more as meaningfully higher risk at any LDL-C.

Coronary artery calcium

When the decision remains uncertain at borderline or intermediate risk, a calcium score refines it.

The 2026 guideline keeps this logic, suggests CAC in men from age 40 and women from 45, and treats any calcium as supporting an LDL-C goal under 100, with higher-intensity therapy at 100 or more or the 75th percentile.

Statin intensity

Simvastatin 80 mg is not started because of myopathy risk. Only atorvastatin and rosuvastatin reach high intensity, which makes "simvastatin 40 mg" a common wrong answer when high intensity is required.

Who gets which intensity

Secondary prevention

Clinical ASCVD at age 75 or younger calls for a high-intensity statin. Over 75, starting or continuing high intensity is reasonable after weighing benefit, adverse effects and patient preference, with moderate intensity an acceptable alternative. The 2026 goals are LDL-C under 70 mg/dL, and under 55 mg/dL for very high-risk ASCVD (in 2018 terms, multiple major events or one major event plus multiple high-risk conditions). If LDL-C stays above goal on the maximally tolerated statin, add ezetimibe or, for very high risk, a PCSK9 monoclonal antibody; the 2026 guideline no longer requires ezetimibe before a PCSK9 inhibitor.

LDL-C of 190 mg/dL or higher

Ages 20 to 75: high-intensity statin with no risk calculation, because risk calculators underestimate lifetime exposure (2018). Add ezetimibe if LDL-C stays at 100 mg/dL or more or falls less than 50 percent. Confirm in the 2026 text the goal it now attaches to this group.

Diabetes

At ages 40 to 75, a moderate-intensity statin regardless of calculated risk; high intensity is reasonable with multiple risk factors or age 50 to 75 (2018). Under the 2026 guideline, adults 40 to 75 with diabetes have an LDL-C goal under 100, or under 70 when PREVENT risk is high.

Primary prevention without diabetes

Under the 2026 tiers, therapy may be considered at borderline risk (3 to under 5 percent) and is advised after a clinician-patient discussion at intermediate risk (5 to under 10 percent), with an LDL-C goal under 100. High risk (10 percent or more) carries a goal under 70 and usually needs high-intensity therapy. Under 2018 rules, the equivalent decisions were moderate intensity from 7.5 percent and high intensity from 20 percent.

The USPSTF (2022) recommends a statin for adults 40 to 75 with at least one risk factor (dyslipidemia, diabetes, hypertension or smoking) and a 10-year risk of 10 percent or more (grade B), selective offering at 7.5 to under 10 percent (grade C), and finds insufficient evidence at 76 and older.

Younger and older adults

PREVENT 30-year risk informs decisions in adults 30 to 59 with low 10-year risk; drug therapy may be considered for those with LDL-C of 160 mg/dL or more, especially with a family history of premature ASCVD. For primary prevention beyond 75, therapy can be considered after discussion, and a CAC of 0 supports deferral.

Monitoring

• Before starting: lipid panel, ALT, and assessment of conditions that raise myopathy risk (hypothyroidism, CKD, interacting drugs). CK is not checked routinely.
• After starting or changing the dose: fasting or nonfasting lipid panel in 4 to 12 weeks to judge adherence and response (2018), then every 3 to 12 months as needed.
• Muscle symptoms: check CK and TSH, stop the statin, and rechallenge once symptoms resolve with a lower dose, a different statin or alternate-day dosing. Most patients with statin-associated muscle symptoms tolerate some statin. CK more than 10 times the upper limit with symptoms is myositis: stop and evaluate for rhabdomyolysis.
• Liver: recheck ALT only if symptoms suggest hepatotoxicity.
• Interactions: simvastatin and lovastatin are limited or avoided with amiodarone, diltiazem, verapamil, strong CYP3A4 inhibitors such as clarithromycin, and large amounts of grapefruit juice. Gemfibrozil should not be combined with a statin.
• Pregnancy: stop statins before planned conception and during pregnancy and breastfeeding.

Refer to a lipid specialist or cardiology for suspected familial hypercholesterolemia not reaching goal, statin intolerance with high risk, triglycerides of 1,000 mg/dL or more, or very high-risk ASCVD above goal despite combination therapy.

Patient education

Explain the absolute risk, not just the LDL-C number, and frame the statin as risk reduction. Teach that muscle aches should be reported rather than tolerated silently or used as a reason to stop. Atorvastatin and rosuvastatin can be taken at any time of day. Diet, activity, weight and smoking cessation remain the foundation. Women of reproductive age need a plan for stopping before conception.

How the exam tests this

• The calculator trap. A stem giving "10-year ASCVD risk 8 percent" is a 2018 item (intermediate: moderate-intensity statin after discussion). "10-year PREVENT risk 8 percent" is a 2026 item (intermediate: therapy after discussion, LDL-C goal under 100). Do not mix the cut-offs.
• The 190 trap. LDL-C of 196 mg/dL with a low calculated risk still gets a high-intensity statin; the calculator does not apply.
• The intensity trap. Simvastatin 40 mg or pravastatin 40 mg is moderate intensity and wrong after a myocardial infarction.
• The add-on trap. Adding ezetimibe to atorvastatin 20 mg after an MI skips the step of maximizing the statin.
• The CK trap. Routine baseline or periodic CK is unnecessary.
• The CAC trap. A score of 0 supports deferring a statin, except in smokers, diabetes or a strong family history.

Practice question

A 58-year-old man is seen 3 months after a non-ST-elevation myocardial infarction treated with a stent. He takes aspirin, clopidogrel, metoprolol succinate, lisinopril and atorvastatin 20 mg daily, and reports no muscle symptoms. Today's LDL-C is 98 mg/dL and ALT is normal. Which of the following is the most appropriate change in lipid therapy?

• A. Add ezetimibe 10 mg daily to atorvastatin 20 mg
• B. Increase atorvastatin to 80 mg daily and recheck a lipid panel in 4 to 12 weeks
• C. Continue the current dose and recheck the lipid panel in 1 year
• D. Switch to simvastatin 40 mg daily

Answer: B. Clinical ASCVD at age 75 or younger calls for a high-intensity statin, and atorvastatin 20 mg is only moderate intensity, so the first step is to raise the dose and recheck in 4 to 12 weeks. Option A adds a nonstatin before the statin has been maximized; ezetimibe comes after high-intensity therapy leaves LDL-C above goal. Option C accepts moderate intensity and an LDL-C well above the goal of under 70 mg/dL. Option D is another moderate-intensity regimen and carries more interaction and myopathy risk than atorvastatin.

Key points

Related NPPace guides

• Atrial Fibrillation in the Clinic: CHA2DS2-VASc, Anticoagulant Choice and Rate Control
• Choosing the First Antihypertensive by Comorbidity: Diabetes, CKD, Heart Failure, Pregnancy and Age
• Heart Failure Follow-Up in Primary Care: GDMT, Weights, Labs and When to Refer
• How to Read a Primary-Care Vignette Like a Provider: The 5-Step Method
• AANP vs ANCC: Which NP Certification Exam Should You Take?